Roivant Sciences (NASDAQ: ROIV) analyst commentary continued through the weekend following Tuesday's Pulmovant Phase 2 PHocus mosliciguat win, with Leerink Partners' David Risinger flagging up to $10 billion peak sales potential for mosliciguat across multiple pulmonary hypertension indications. The Leerink estimate substantially exceeds the ~$3 billion PH-ILD-only estimate Guggenheim disclosed Wednesday September 9. Other analyst peak sales projections ranged from $1.5 billion to $5 billion depending on indication assumptions and market-share methodology. The week's analyst upgrade sequence: Jefferies to $52 (from $42), Guggenheim to $46 (from $42), Piper Sandler to $55 (from $40), TD Cowen to $55 (from $50), BofA also raised. Consensus 12-month price target clusters around $50-55. The PHocus trial produced a 56.3% placebo-adjusted PVR reduction at Week 16 (p<0.0001), 6MWD +35.2 meters, and NT-proBNP −357.7 pg/mL (−53.2%). The Phase 3 PHrontier trial in approximately 375 patients is enrolling. Mosliciguat's mechanism (inhaled soluble guanylate cyclase activator working independently of heme and nitric oxide) differentiates it from sGC stimulators like Bayer's Adempas (riociguat) and prostacyclin analogs like United Therapeutics' Tyvaso (treprostinil).
Sell-side analyst upgrades on Roivant Sciences (NASDAQ: ROIV) continued through Wednesday-Thursday September 9-10, 2026 following the Tuesday September 8 Pulmovant Phase 2 PHocus win in pulmonary hypertension associated with interstitial lung disease. TD Cowen raised its ROIV price target to $55 from $50 with a Buy rating; Jefferies raised to $52 from $42 with a Buy rating. These upgrades follow the Guggenheim ($46 from $42) and Piper Sandler ($55 from $40) targets published Wednesday September 9. Guggenheim estimated peak sales of approximately $3 billion in PH-ILD. Consensus analyst estimates now cluster around a $50-55 target range. The PHocus study achieved a 56.3% placebo-adjusted reduction in pulmonary vascular resistance at Week 16 (p<0.0001) with placebo-adjusted improvements of +35.2 meters six-minute walk distance and −53.2% NT-proBNP from baseline. The Phase 3 PHrontier study is enrolling approximately 375 patients globally in a 1:1 randomized double-blind placebo-controlled design.
Sell-side analysts moved fast Wednesday September 9, 2026 following Tuesday's positive Phase 2 PHocus readout from Roivant Sciences (NASDAQ: ROIV) subsidiary Pulmovant. Guggenheim raised its ROIV price target to $46 from $42 while maintaining a Buy rating, and Guggenheim estimated peak sales of approximately $3 billion in pulmonary hypertension associated with interstitial lung disease. Piper Sandler analyst Yasmeen Rahimi raised her price target to $55 from $40 with an Overweight rating. Roivant shares closed up approximately 17% Tuesday on the ERS Congress presentation of a 56.3% placebo-adjusted reduction in pulmonary vascular resistance at Week 16 (p<0.0001), plus placebo-adjusted improvements of +35.2 meters six-minute walk distance and −357.7 pg/mL NT-proBNP (−53.2% from baseline). The Phase 3 PHrontier study in approximately 375 patients is enrolling. If PHrontier confirms the Phase 2 signal, mosliciguat would land in a PH-ILD market currently anchored by United Therapeutics' Tyvaso (treprostinil) — the only FDA-approved therapy specifically for PH-ILD — with orally-administered Merck Winrevair (sotatercept) as a pulmonary arterial hypertension option positioned differently.
Pulmovant, a Roivant Sciences (NASDAQ: ROIV) company, announced Tuesday September 8, 2026 that the Phase 2 PHocus study of inhaled mosliciguat (a once-daily first-in-class inhaled soluble guanylate cyclase activator) met its primary endpoint in patients with pulmonary hypertension associated with interstitial lung disease. Placebo-adjusted pulmonary vascular resistance reduction was 56.3% at Week 16 (-51.3% mosliciguat vs +6.6% placebo, p<0.0001) — the largest PVR reduction reported in any randomized controlled pulmonary hypertension trial per Pulmovant. Secondary endpoints: placebo-adjusted six-minute walk distance +35.2 meters (p=0.0027) and NT-proBNP -357.7 pg/mL, a 53.2% reduction from baseline (p=0.0002). At Week 24 (exploratory), 6MWD was +52.7 meters placebo-adjusted and NT-proBNP was -487.1 pg/mL (-75.9%). Mosliciguat was well-tolerated with lower cough incidence (12.1%) than placebo (18.2%). The trial enrolled 135 patients across 87 sites in 20 countries. The Phase 3 PHrontier study is enrolling approximately 375 patients globally in a 1:1 randomized double-blind placebo-controlled design. Marc Humbert (Université Paris-Saclay) presented the data at the ERS Congress in Barcelona; Roivant shares closed up approximately 17% on the day. Mosliciguat activates sGC independently of heme and nitric oxide, differentiating it from sGC stimulators like riociguat.
Roivant Sciences (NASDAQ: ROIV) and its Pulmovant subsidiary announced Sunday September 6, 2026 that Phase 2 PHocus topline results for mosliciguat (a once-daily inhaled soluble guanylate cyclase activator) in pulmonary hypertension associated with interstitial lung disease (PH-ILD) will be presented Tuesday September 8, 2026 at 12:15 CEST (6:15 a.m. ET) at the European Respiratory Society Congress 2026 in Barcelona by Marc Humbert MD PhD (Université Paris-Saclay; French National Reference Center for Pulmonary Hypertension). The randomized double-blind placebo-controlled global trial enrolled 135 adults with PH-ILD; the primary endpoint is change from baseline in pulmonary vascular resistance at week 16, with the controlled period running through week 24. Roivant will host an investor call at 8:00 a.m. ET the same day. Mosliciguat is an sGC activator that works independently of heme and nitric oxide, differentiating it from sGC stimulators like riociguat. In the earlier Phase 1b ATMOS study a single inhaled dose produced a mean peak reduction in pulmonary vascular resistance of up to 38%. The PVR change versus placebo is the metric investors are watching; the same endpoint anchored the Phase 3 program for United Therapeutics' Tyvaso (treprostinil) in PH-ILD.
Roivant Sciences (NASDAQ: ROIV) subsidiary Priovant Therapeutics announced FDA approval of Lisraya (brepocitinib 30 mg once daily, a first-in-class TYK2/JAK1 dual selective inhibitor) on Thursday August 27, 2026 for adults with dermatomyositis (DM), an autoimmune inflammatory myopathy with skin involvement and few effective targeted therapies. Approval was based on the 52-week Phase 3 VALOR trial (241 patients, the longest and largest interventional DM study), where 55% of Lisraya patients achieved moderate-or-better improvement on the Total Improvement Score with minimal-or-no steroid use versus 30% on placebo. VALOR results were published in NEJM in March 2026 with dermatology secondary endpoints in JAMA Dermatology in August 2026. List price is $35,000 for a 30-day supply, with a $0/month patient support program for eligible patients. Brepocitinib was originally discovered by Pfizer and licensed to Priovant. Not a peptide; the approval matters here because dermatomyositis is one of several autoimmune indications where peptide immunomodulators (thymalfasin, thymosin alpha-1 analogs) had been discussed in earlier decades before being displaced by targeted small-molecule and biologic approaches.
Alongside the FDA approval announcement Thursday August 27, 2026, Roivant Sciences (NASDAQ: ROIV) filed an 8-K disclosure and hosted a conference call Friday August 28, 2026 confirming that Priovant Therapeutics has fielded a dermatology-and-rheumatology-focused sales force, contracted with major specialty pharmacy distributors, and secured initial payer coverage sufficient to begin U.S. commercial launch on August 28. Priovant is a Pfizer-Roivant joint venture (Roivant 75%, Pfizer 25%) that was created in 2022 specifically to advance brepocitinib in dermatomyositis, cutaneous lupus, and non-infectious uveitis. Beyond Lisraya, Priovant's brepocitinib program continues in Phase 3 for cutaneous lupus (VALIANT) with topline data expected in H1 2027 and in Phase 2 for non-infectious uveitis. The launch is a signal event for the Roivant 'Vant' model, in which spin-out subsidiaries develop and commercialize discrete assets while remaining consolidated within the parent. Not a peptide; included because the JAK/TYK2 inhibitor category continues to displace older peptide-based immunomodulation approaches in autoimmune disease.